Adverse effects and safety of SGLT-2 inhibitors (Q28082331)

B. Vergès

series ordinal

2

1 reference

language of work or name

1 reference

December 2014

1 reference

published in

Diabetes and Metabolism

1 reference

volume

40

1 reference

issue

6 Suppl 1

1 reference

page(s)

S28-34

1 reference

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Determining predictors of response to exenatide in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

The Sweet Pee model for Sglt2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

The economic and quality of life impact of hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Urinary tract infections in patients with diabetes treated with dapagliflozin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972693-X

7 January 2021